Autres langues Gilead Sciences, Inc. Sao Paulo

Actions

GILD34

BRGILDBDR000

Produits pharmaceutiques

Marché Fermé - Sao Paulo 21:52:23 17/09/2026			Varia. 5j.	Varia. 1 janv.
64,64 ^BRL	+1,64%		+5,97%	+12,75%

16/09	Gilead Sciences : une dirigeante cède des actions pour 432 646 dollars, selon un document de la SEC	MT
16/09	Gilead Sciences, Inc. élargit ses accords de licence volontaire sans redevance pour le lenacapavir avec Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero et Mylan Laboratories Limited	CI

Autres langues

16/09	Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing
16/09	Gilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories Limited
16/09	Gilead Sciences Expands Licensing Agreements for HIV Treatment
16/09	Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
15/09	Gilead Sciences, Inc. and Pan American Health Organization Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
15/09	Gilead Sciences Expands Lenacapavir Access to 14 Countries
15/09	Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
15/09	Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
08/09	Assembly Biosciences Exercises Option to Share US Costs, Profits for Herpes Program With Gilead
08/09	Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
08/09	Assembly Biosciences, Inc. and Gilead Sciences, Inc. Exercise U.S. Profit-Share Option for HSV Helicase-Primase Inhibitor Program
08/09	Gilead Sciences Opens Research Center At Foster City Headquarters
08/09	Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
07/09	Gilead Sciences Announces FDA Approval for Bixlenvo as A Once-Daily Single Tablet Option for Virologically Suppressed Adults with Hiv
03/09	AbbVie's blood cancer therapy lowers disease progression, death risk in trial
01/09	Global pharma companies that have publicly announced Trump drug pricing agreements
28/08	Afternoon Meeting: Warsh entra en escena
28/08	Warsh Takes the Stage
28/08	Morning Meeting: Zwei Märkte, zwei Geschichten
28/08	A tale of two markets
28/08	Gilead Sciences : Breaks Ground on New Biologics Facility as Part of $32 Billion U.S. R&D and Manufacturing Investment
28/08	Gilead Sciences Wins FDA Approval for HIV Pill Bixlenvo
27/08	US FDA approves Gilead's once-daily combination pill for HIV treatment
27/08	U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
27/08	Gilead Sciences Announces FDA Approval Of Bixlenvo For Virologically Suppressed Adults With HIV